Proposed Classes Ask To Combine Janssen Antitrust Suits

Law360 (June 3, 2019, 5:10 PM EDT) -- Four proposed classes suing Janssen Biotech for allegedly using sham patent litigation to keep a generic version of its prostate cancer drug off the market want a Virginia federal court to consolidate their suits so they can team up against the pharmaceutical giant.

The proposed classes, which include the city of Baltimore and Blue Cross Blue Shield of Louisiana, posed their request Friday, saying it would save the court time and resources if they were able to act as one.

“Given the four cases’ common questions of law and fact — they involve the same allegations of sham litigation against the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Judge

Subscribers Only

Date Filed

April 18, 2019


Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Judge

Subscribers Only

Date Filed

May 16, 2019


Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Judge

Subscribers Only

Date Filed

May 24, 2019


Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Judge

Subscribers Only

Date Filed

May 28, 2019

Law Firms

Companies

Government Agencies